Form 4: Director A. Clayton Perfall Acquires Enovis Shares

Enovis Corporation Director A. Clayton Perfall acquired 9,346 shares of common stock as part of a compensation grant.

Summary

• Director A. Clayton Perfall acquired 9,346 shares of Enovis Corp (ENOV) common stock on May 19, 2026.
• The shares were acquired at a price of $0.00, indicating an equity compensation grant.
• Following this transaction, the director's direct beneficial ownership increased to 54,190 shares.
• The director maintains an additional indirect holding of 2,482 shares held by a trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Increased alignment between director interests and shareholder value through higher equity ownership.

Negatives

• None identified.

Risks

• General market risks associated with equity ownership in the medical technology sector.

Future Outlook

Not applicable as this is a routine insider transaction filing.

Industry Context

StockSavvy.ai notes that director equity grants are standard practice in the medical device industry to ensure long-term alignment with corporate performance goals.

Comparison to Industry Standards

• The acquisition is consistent with standard director compensation packages for mid-cap medical technology firms.

Stakeholder Impact

• Positive signal for shareholders as it reflects director commitment to the company.

Key Dates

Keywords

Enovis, ENOV, Insider Trading, Form 4, Director Acquisition, Equity Compensation